A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The Phase I trial of the Survivin long peptide vaccine (SurVaxM) is sponsored by Roswell Park Cancer Institute and focuses on patients with metastatic neuroendocrine tumors (NETs). Given the limited treatment options for advanced NETs, this vaccine could represent a novel immunotherapeutic approach, potentially enhancing the immune response against tumors expressing survivin. The market for NET therapies is growing, with increasing incidence rates and a demand for innovative treatments. Competitive analysis indicates that while somatostatin analogs are standard care, there is a gap for immunotherapies, positioning SurVaxM favorably. Diligence should focus on safety and efficacy data as well as potential partnerships for further development and commercialization.
Indication: Lung Atypical Carcinoid Tumor
Modality: protein therapy
Target: Survivin long peptide vaccine (SVN53-67/M57-KLH) targeting survivin protein expressed in neuroendocrine tumors.
Sponsor: Roswell Park Cancer Institute
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Survivin long peptide vaccine (SVN53-67/M57-KLH) targeting survivin protein expressed in neuroendocrine tumors.
View original source fields
Condition raw: Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
Condition normalized: Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Survivin long peptide vaccine (SVN53-67/M57-KLH) targeting survivin protein expressed in neuroendocrine tumors.
Target normalized: Survivin long peptide vaccine (SVN53-67/M57-KLH) targeting survivin protein expressed in neuroendocrine tumors.